Neoadjuvant immune checkpoint inhibitors in high-risk stage III melanoma

References

• Gershenwald JE, Scolyer RA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol. 2018;25(8):2105–2110.
   Web of Science ®Google Scholar
• Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RM Jr, Kugler J, Rodrigue LJ. Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol. 1995;2776–11. doi:https://doi.org/10.1200/JCO.1995.13.11.2776
   Google Scholar
• Ascierto PA, Gogas HJ, Grob JJ, Algarra SM, Mohr P, Hansson J, Hauschild A. Adjuvant interferon alfa in malignant melanoma: an interdisciplinary and multinational expert review. Crit Rev Oncol Hematol. 2013;85(2):149–61. doi:https://doi.org/10.1016/j.critrevonc.2012.07.004.
   PubMed Web of Science ®Google Scholar
• Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Cil Cancer Res. 2004;10(5):1670–77. doi:https://doi.org/10.1158/1078-0432.CCR-1103-3.
   PubMed Web of Science ®Google Scholar
• Malczewski A, Marshall A, Payne MJ, Mao L, Bafaloukos D, Si L, Pectasides D, Fountzilas G, Guo J, Gogas H, et al. Intravenous high‐dose interferon with or without maintenance treatment in melanoma at high risk of recurrence: meta‐analysis of three trials. Cancer Med. 2016 Jan;5(1):17–23.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Del Vecchio M, Mandalá M, Gogas H, Arance AM, Dalle S, Cowey CL, Schenker M, Grob -J-J, Chiarion-Sileni V, et al. Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(11):1465–77. doi:https://doi.org/10.1016/S1470-2045(20)30494-0.
   PubMed Web of Science ®Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson VG, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Prognostic and predictive value of AJCC-8 staging in the phase III EORTC1325/KEYNOTE-054 trial of pembrolizumab vs placebo in resected high-risk stage III melanoma. Eur J Cancer. 2019;116:148–57. doi:https://doi.org/10.1016/j.ejca.2019.05.020.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16(5):522–30. doi:https://doi.org/10.1016/S1470-2045(15)70122-1.
   PubMed Web of Science ®Google Scholar
• Owen CN, Shoushtari AN, Chauhan D, Palmieri DJ, Lee B, Rohaan MW, Mangana J, Atkinson V, Zaman F, Young A, et al. Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy. Ann Oncol. 2020;31(8):1075–82. doi:https://doi.org/10.1016/j.annonc.2020.04.471.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnefoi H, Cameron D, Gianni L, Valagussa P, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2019;384(9938):164–72. doi:https://doi.org/10.1016/S0140-6736(13)62422-8.
   Web of Science ®Google Scholar
• Amaria RN, Menzies AM, Burton EM, Scolyer RA, Tetzlaff MT, Antdbacka R, Ariyan C, Bassett R, Carter B, Daud A, et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol. 2019;20(7):e378–89. doi:https://doi.org/10.1016/S1470-2045(19)30332-8.
   PubMed Web of Science ®Google Scholar
• Lui VK, Karpuchas J, Dent PB, McCulloch PB, Blajchman MA. Cellular immunocompetence in melanoma: effect of extent of disease and immunotherapy. Br J Cancer. 1975;32(3):323–30. doi:https://doi.org/10.1038/bjc.1975.230.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu W-J, Hanna E, et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(11):1649–54. doi:https://doi.org/10.1038/s41591-018-0197-1.
   PubMed Web of Science ®Google Scholar
• Amaria RN, Reddy SM, Tawbi HA, Davies MA, Ross MI, Glitza IC, Cormier JN, Lewis C, Hwu WJ, Hanna E, et al. Publisher correction: neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med. 2018;24(12):1942. doi:https://doi.org/10.1038/s41591-018-0252-y.
   PubMed Web of Science ®Google Scholar
• Polak ME, Borthwick NJ, Gabriel FG, Johnson P, Higgins B, Hurren J, McCormick D, Jager MJ, Cree IA. Mechanisms of local immunosuppression in cutaneous melanoma. Br J Cancer. 2007;96(12):1879–87. doi:https://doi.org/10.1038/sj.bjc.6603763.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Menzies AM, Van Akkooi ACJ, Adhikari C, Bierman C, van de Wiel BA, Scolyer RA, Krijgsman O, Sikorska K, Eriksson H, et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 2019;20(7):948–60. doi:https://doi.org/10.1016/S1470-2045(19)30151-2.
   PubMed Web of Science ®Google Scholar
• Rozeman EA, Hoefsmit EP, Reijers ILM, Saw RPM, Versluis JM, Krijgsman O, Dimitriadis P, Sikorska K, van de Wiel BA, Eriksson H, et al. Survival and biomarker analyses from the OpACIN-neo and OpACIN neoadjuvant immunotherapy trials in stage III melanoma. Nat Med. 2021;27(2):256–63. doi:https://doi.org/10.1038/s41591-020-01211-7.
   PubMed Web of Science ®Google Scholar
• Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723. doi:https://doi.org/10.1056/NEJMoa1003466.
   PubMed Web of Science ®Google Scholar
• Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. Prolonged survival in stage III melanoma with Ipilimumab adjuvant therapy. Med N Engl J. 2016;375(19):1845–55. Erratum in: N Engl J Med. 2018., p. 379(22):2185. doi:https://doi.org/10.1056/NEJMoa1611299.
   PubMed Web of Science ®Google Scholar
• Tarhini AA, Edington H, Butterfield LH, Lin Y, Shuai Y, Tawbi H, Sander C, Yin Y, Holtzman M, Johnson J, et al. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab. PLoS One. 2014;9(2):e87705. doi:https://doi.org/10.1371/journal.pone.0087705.
   PubMed Web of Science ®Google Scholar
• Tarhini A, Lin Y, Lin H, Rahman Z, Vallabhaneni P, Mendiratta P, Pingpank JF, Holtzman MP, Yusko EC, Rytlewski JA, et al. Neoadjuvant ipilimumab (3 mg/kg or 10 mg/kg) and high dose IFN-α2b in locally/regionally advanced melanoma: safety, efficacy and impact on T-cell repertoire. J Immunother Cancer. 2018;6(1):112. doi:https://doi.org/10.1186/s40425-018-0428-5.
   PubMed Web of Science ®Google Scholar
• Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015;33(17):1974‐1982. doi:https://doi.org/10.1200/JCO.2014.59.4358.
   Google Scholar
• Schachter J, Ribas A, Long GV, Arance A, Grob -J-J, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open‐label phase 3 study (KEYNOTE‐006). Lancet. 2017;390(10105):1853‐1862. doi:https://doi.org/10.1016/S0140-6736(17)31601-X.
   Google Scholar
• Hodi FS, Chiarion‐Sileni V, Gonzalez R, Grob -J-J, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4‐year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19(11):1480–1492. doi:https://doi.org/10.1016/S1470-2045(18)30700-9.
   PubMed Web of Science ®Google Scholar
• Huang AC, Orlowski RJ, Xu X, Mick R, George SM, Yan PK, Manne S, Kraya AA, Wubbenhorst B, Dorfman L, et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med. 2019;25(3):454–61. doi:https://doi.org/10.1038/s41591-019-0357-y.
   PubMed Web of Science ®Google Scholar
• Huang AC, Xu X, Orlowski RJ, Sangeeth MG, Chilukuri L, Kozlov A, Carberry M, Giles L, McGettigan S, Kreider K, et al. Safety, activity, and biomarkers for neoadjuvant anti-PD-1 therapy in melanoma. Abstract CT181. Clin Trials. 2018;2018:78.
   Google Scholar
• Eggermont AMM, Blank CU, Mandala M, Long GV, Atkinson V, Dalle S, Haydon A, Lichinitser M, Khattak A, Carlino MS, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N Engl J Med. 2018;378(19):1789–801. doi:https://doi.org/10.1056/NEJMoa1802357.
   PubMed Web of Science ®Google Scholar
• Blank CU, Versluis JM, Reijers ILM, Sikorska K, van Houdt WJ, van Thienen JV, Adriaansz S, Mallo HA, Van Tinteren H, van de Wiel BA, et al. 3-years relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant Ipilimumab (IPI) + Nivolumab (NIVO) in macroscopic stage III melanoma (OPACIN TRIAL). Ann Oncol. 2019;30(Suppl. 5):v533–v563. doi:https://doi.org/10.1093/annonc/mdz255.003.
   Google Scholar
• Lebbé C, Meyer N, Mortier L, Marquez-Rodas I, Robert C, Rutkowski P, Menzies AM, Eigentler T, Ascierto PA, Smylie M, et al. Two dosing regimens of nivolumab plus ipilimumab for advanced melanoma: 3-year results of CheckMate 511. ASCO. Presentation number 9516; 2021.
   Google Scholar
• Long GV, Schadendorf D, Del Vecchio M, Larkin J, Atkinson V, Schenker M, Pigozzo J, Gogas HJ, Dalle S, Meyer N, et al. Adjuvant therapy with nivolumab (NIVO) combined with ipilimumab (IPI) vs NIVO alone in patients (pts) with resected stage IIIB-D/IV melanoma (CheckMate 915). AACR. Abstract CT004; 2021.
   Google Scholar
• Schermers B, Franke V, Rozeman EA, van de Wiel BA, Bruining A, Wouters MW, van Houdt WJ, ten Haken B, Muller SH, Bierman C, et al. Surgical removal of the index node marked using magnetic seed localization to assess response to neoadjuvant immunotherapy in patients with stage III melanoma. Br J Surg. 2019;106(5):519–22. doi:https://doi.org/10.1002/bjs.11168.
   PubMed Web of Science ®Google Scholar
• Blank CU, Reijers ILM, Pennington T, Versluis JM, Saw RP, Rozeman EA, Kapiteijn E, Van Der Veldt AAM, Suijkerbuijk K, Hospers G, et al. First safety and efficacy results of PRADO: a phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma. J Clin Oncol. 2020;38(15_suppl):10002–10002. s.l.: Clinical trial information: NCT02977052. doi:https://doi.org/10.1200/JCO.2020.38.15_suppl.10002.
   Web of Science ®Google Scholar
• Van Den Heuvel NMJ, Reijers ILM, Versluis JM, Rozeman AE, Jóźwiak K, Blommers KH, Saw RPM, Suijkerbuijk KPM, Kapiteijn E, Van der Veldt AAM, et al. 1085P-health-related quality of life in stage III melanoma patients treated. Ann Oncol. 2020.  31:S737. Clinical trial information OpACIN-neo/PRADO extension cohort NCT02977052.
   PubMed Web of Science ®Google Scholar
• Woo SR, Turnis ME, Goldberg MG, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, et al. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. Cancer Res. 2012;72:917–927.
   PubMed Web of Science ®Google Scholar
• Anderson AC, Joller N, Kuchrooet VK. Lag-3, tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity. 2016;44(5):989–1004. doi:https://doi.org/10.1016/j.immuni.2016.05.001.
   PubMed Web of Science ®Google Scholar
• Ascierto PA, Melero I, Bhatia S,Bono P, Sanborn RE, Lipson EJ, Callahan MK, Gajewski T, Gomez-Roca CA, Hodi FS, et al. Initial efficacy of anti-lymphocyte activation gene-3 (Anti–LAG-3; BMS986016) in combination with nivolumab (Nivo) in pts with melanoma (MEL) previously treated with anti–PD-1/PD-L1 therapy. J Clin Oncol. 2017;35(15_suppl):9520. doi:https://doi.org/10.1200/JCO.2017.35.15_suppl.9520.
   Web of Science ®Google Scholar
• Ascierto PA, Bono P, Bhatia S,Melero I, NyakasI MS, Svane M, Larkin J, Gomez-Roca C, Schadendorf D, Dummer R, et al. Efficacy of BMS-986016, a monoclonal antibody that targets lymphocyte activation gene-3 (LAG-3), in combination with nivolumab in pts with melanoma who progressed during prior anti–PD-1/PD-L1 therapy in all-comer and biomarker-enriched populations. ESMO, Abstract LBA18; 2017.
   Google Scholar
• Amaria RN, Postow M, Tetzlaff MT,Ross MI, Glitza IC, McQuade JL, Wong MKK, Gershenwald JE, Goepfert R, Keung EZY, et al. Neoadjuvant AND adjuvant nivolumab with anti-lag3 antibody relatlimab for patients with resectable clinical stage III melanoma. ASCO; 2021.
   Google Scholar
• Tronnier M, Mitteldorf C. Treating advanced melanoma: current insights and opportunities. Cancer Manag Res. 2014;6:349–56. doi:https://doi.org/10.2147/CMAR.S49494.
   PubMed Web of Science ®Google Scholar
• Parato KA, Senger D, Forsyth PA, Bell JC. Recent progress in the battle between oncolytic viruses and tumours. Nat Rev Cancer. 2005;5(12):965–76. 26. doi:https://doi.org/10.1038/nrc1750.
   PubMed Web of Science ®Google Scholar
• Forbes NE, Krishnan R, Diallo JS. Pharmacological modulation of antitumor immunity induced by oncolytic viruses. Front Oncol. 2014;4(191):27. doi:https://doi.org/10.3389/fonc.2014.00191.
   PubMedGoogle Scholar
• Russell SJ, Peng KW, Bell JC. Oncolytic virotherapy. Nat Biotechnol. 2012;30(7):658–70. doi:https://doi.org/10.1038/nbt.2287.
   PubMed Web of Science ®Google Scholar
• Andtbacka RH, Kaufman HL, Collichio F, Amatruda T, Senzer N, Chesney J, Delman KA, Spitler LE, Puzanov I, Agarwala SS,et al. Talimogene laherparepvec improves durable response. Clin Oncol. 2015;33(25):2780–88.
   Web of Science ®Google Scholar
• Dummer R, Gyorki D, Hyngstrom J,Berger AC, Conry RM, Demidov LV, Sharma A, Treichel S, Faries MB, Ross MI. Improved Recurrence-Free Survival (RFS) from a randomized phase 2 study of Neoadjuvant (Neo) Talimogene Laherparepvec (T-VEC) Plus Surgery (Surg) vs Surg for resectable stage IIIB-IVM1a Melanoma (MEL). Presented At: The 16th International Congress of the Society for Melanoma Research. Salt Lake City, UT-2019.
   Google Scholar
• Dummer R, Gyorki D, Hyngstrom J, Berger A, Conry R, Demidov L, Chan E, Radcliffe H-S, Faries M, Ross M, et al. 3- year results of the phase 2 randomized trial for Talimogene Laherparepvec (T-VEC) Neoadjuvant treatment plus surgery vs Surgery in patients with resectable stage IIIB-IVM1a Melanoma. J Immunother Cancer. 2020. doi:https://doi.org/10.1136/jitc-2020-SITC2020.0432.
   Google Scholar
• Davar D, Karunamurthy A, Hartman D,De Blasio R, Chauvin JM, Ding Q, Pagliano O, Rose A, Kirkwood J and Zarour H. Phase II trial of Neoadjuvant Nivolumab (Nivo) and Intra-Tumoral (it) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): preliminary results. Presented At SITC 2019. J ImmunoTher Cancer. 2020;8.
   Google Scholar
• Davar D, Karunamurthy A, Hartman D, DeBlasio R, Chauvin J-M, Ding Q, Pagliano O, Rose A, Kirkwood J, Zarour H, et al. Phase II trial of Neoadjuvant Nivolumab (Nivo) and intra-tumoral (it) CMP-001 in high-risk resectable melanoma (Neo-C-Nivo): final results. J Immunother Cancer. 2020;8(Suppl 3):A330–A330. doi:https://doi.org/10.1136/jitc-2020-SITC2020.0303.
   Web of Science ®Google Scholar
• Menzies AM, Amaria RN, Rozeman EA, Huang AC, Tetzlaff MT, van de Wiel BA, Lo S, Tarhini AA, Burton EM, Pennington TE, et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium. Nat Med. 2021;27(2):301–09. doi:https://doi.org/10.1038/s41591-020-01188-3.
   PubMed Web of Science ®Google Scholar
• Schadendorf D, Wolchok JD, Hodi FS, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob -J-J, Cowey CL, Lao CD, Chesney J, et al. Efficacy and safety outcomes in patients with advanced melanoma who discontinued treatment with nivolumab and ipilimumab because of adverse events: a pooled analysis of randomized phase II and III trials. J Clin Oncol. 2017;35(34):3807–14. doi:https://doi.org/10.1200/JCO.2017.73.2289.
   PubMed Web of Science ®Google Scholar
• Ugurel S, Röhmel J, Ascierto PA, Becker JC, Flaherty KT, Grob JJ, Hauschild A, Larkin J, Livingstone E, Long GV, et al. Survival of patients with advanced metastatic melanoma: the impact of MAP kinase pathway inhibition and immune checkpoint inhibition - update 2019. Eur J Cancer. 2020;130:126–38. doi:https://doi.org/10.1016/j.ejca.2020.02.021.
   PubMed Web of Science ®Google Scholar
• Moschos SJ, Edington HD, Land SR, Rao UN, Jukic D, Shipe-Spotloe J, Kirkwood JM. Neoadjuvant treatment of regional stage IIIB melanoma with high-dose interferon alfa-2b induces objective tumor regression in association with modulation of tumor infiltrating host cellular immune responses. Oncol J Clin. 2006;24(19):3164–71. doi:https://doi.org/10.1200/JCO.2005.05.2498.
   PubMed Web of Science ®Google Scholar
• Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, et al; RECIST working group. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2019 May; 20(5): e242. Erratum in: Lancet Oncol. PMID: 28271869; PMCID: PMC5648544. 2017, p. 18(3):e143-e152.
   Web of Science ®Google Scholar
• Trebeschi S, Drago SG, Birkbak NJ, Kurilova I, Cǎlin AM, Delli Pizzi A, Lalezari F, Lambregts DMJ, Rohaan MW, Parmar C, et al. Predicting response to cancer immunotherapy using noninvasive radiomic biomarkers. Ann Oncol. 2019;30(6):998–1004. doi:https://doi.org/10.1093/annonc/mdz108.
   PubMed Web of Science ®Google Scholar
• Dummer R, Brase JC, Garrett J, Campbell CD, Gasal E, Squires M, Gusenleitner D, Santinami M, Atkinson V, Mandalà M, et al. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAFV600-mutant, stage III melanoma (COMBI-AD): exploratory biomarker analyses from a randomised, phase 3 trial. Lancet Oncol. 2020;21(3):358–72. doi:https://doi.org/10.1016/S1470-2045(20)30062-0.
   PubMed Web of Science ®Google Scholar